1
|
Rathod R, Mahendran K, Sproat C. NFC for PILs. Br Dent J 2023; 234:361. [PMID: 36964343 DOI: 10.1038/s41415-023-5696-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 02/28/2023] [Indexed: 03/26/2023]
|
2
|
Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, Sharma A, Ranvir R, Kadam S, Ingale K, Patel H, Nyska A, Jain MR. Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. BMC Cancer 2023; 23:59. [PMID: 36650455 PMCID: PMC9843913 DOI: 10.1186/s12885-023-10530-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Accepted: 01/09/2023] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Saroglitazar is a novel PPAR-α/γ agonist with predominant PPAR-α activity. In various preclinical models, saroglitazar has been shown to prevent & reverse symptoms of NASH. In view of these observations, and the fact that NASH is a progressive disease leading to HCC, we hypothesized that saroglitazar may prevent the development of HCC in rodents. METHODS HCC was induced in C57BL/6 mice by a single intraperitoneal injection of 25 mg/kg diethylnitrosamine (DEN) at the age of 4 weeks and then feeding the animal a choline-deficient, L-amino acid- defined, high-fat diet (CDAHFD) for the entire study duration. Eight weeks after initiation of CDAHFD, saroglitazar (1 and 3 mg/kg) treatment was started and continued for another 27 weeks. RESULTS Saroglitazar treatment significantly reduced the liver injury markers (serum ALT and AST), reversed hepatic steatosis and decreased the levels of pro-inflammatory cytokines like TNF-α in liver. It also resulted in a marked increase in serum adiponectin and osteopontin levels. All disease control animals showed hepatic tumors, which was absent in saroglitazar (3 mg/kg)- treatment group indicating 100% prevention of hepatic tumorigenesis. This is the first study demonstrating a potent PPARα agonist causing suppression of liver tumors in rodents, perhaps due to a strong anti-NASH activity of Saroglitazar that overrides its rodent-specific peroxisome proliferation activity. CONCLUSION The data reveals potential of saroglitazar for chemoprevention of hepatocellular carcinoma in patients with NAFLD/NASH.
Collapse
Affiliation(s)
- Suresh R. Giri
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Bibhuti Bhoi
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Chitrang Trivedi
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Akshyaya Rath
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Rohan Rathod
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Anish Sharma
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Ramchandra Ranvir
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Shekhar Kadam
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Kailash Ingale
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Hiren Patel
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| | - Abraham Nyska
- grid.12136.370000 0004 1937 0546Tel Aviv University, Yehuda HaMaccabi 31, floor 5, 6200515 Tel Aviv, Israel
| | - Mukul R. Jain
- grid.465119.e0000 0004 1768 0532Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), Sarkhej-Bavla N.H.No. 8A, Moraiya, Ahmedabad, Gujarat 382213 India
| |
Collapse
|
3
|
Rathod R, Thakre PP, Ade V. Evaluation of efficacy of Navakarshik Kwath Ghan in Sheetpitta with special reference to Urticaria. IJAM 2020. [DOI: 10.47552/ijam.v11i3.1624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Background: Sheetapitta (Urticaria) is one among the Tvak Vikara (Skin disease) that have similar Hetu (Cause) of Kotha and Udarda. Vata and Kapha are two "Doshas" (energies), which are primarily, disturbed which in turn is associated with Pitta resulting in Tridosha Prakopa (Aggravation of three energies) leading to redness, swelling itching on the skin etc. Symptoms include appearance of wheals all over the body with severe itching, burning sensation and pain. Symptomatology and causative factors of Sheetapitta can be considered similar to that of 'Urticaria'. Aim: This clinical study was carried out to evaluation of efficacy in Sheetpitta with special reference to Urticaria. Material – Navakarshik Kwath Ghan in dose of 2 tab of 500 mg twice a day with water after meal in duration of 15 days. Methodology – In this study include single group of 30 subjects of either gender in the age group of 16-60 years having complaining of reddish wheals, itching and pricking pain on body. Observation and Result – Data regarding age wise, sex wise, allergy wise, diet wise, Prakruti (Nature) wise, hematological parameters and UAS (Urticarial Activity Score). Conclusion – Internal use of Navakarshik Kwath Ghan is found effective in the severity of itching.
Collapse
|
4
|
Ragavan P, Kaur A, Kumar M, Singhal V, Patel A, Khunt A, Shah R, Wazeer S, Rathod R, Mane A, Mehta S, Veligandla K. Retrospective analysis of EMR database to assess the effectiveness of Saccharomyces boulardii CNCM I-745 in children with acute diarrhoea during routine clinical practice. New Microbes New Infect 2020; 38:100766. [PMID: 33093961 PMCID: PMC7568184 DOI: 10.1016/j.nmni.2020.100766] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Revised: 09/14/2020] [Accepted: 09/16/2020] [Indexed: 12/23/2022] Open
Abstract
This study aimed to assess the efficacy of Saccharomyces boulardii, a yeast probiotic, in the management of acute diarrhoeal disorders in the paediatric population in outpatient settings. It was a multicentre retrospective analysis of medical records of children who were treated for acute diarrhoea by routine treatment (oral rehydration solution and zinc) with or without S. boulardii. Overall, 160 children presenting with acute diarrhoea at seven different outpatient paediatric settings were included in the study. Children were divided into two categories based on their treatment with S. boulardii (SB group) or without S. boulardii (Non-SB group). Baseline demographic, anthropometric and clinical variables were compared between the two groups. The median duration of diarrhoea post-treatment was significantly shorter in the S. boulardii group (3 days) than in the non-SB group (4 days). A significant reduction in the frequency of stools was observed post-treatment in the S. boulardii group (1.7 versus 2.5 in the non-SB group). There was a significant weight gain in the S. boulardii group post-treatment (300 g) in comparison with the non-SB group (mean loss of 400 g). This study established the positive role of S. boulardii in the management of acute diarrhoeal diseases in children. Moreover, the S. boulardii probiotic was seen to be effective in diarrhoeal diseases in children with dehydration.
Collapse
Affiliation(s)
| | - A. Kaur
- THB, Gurgaon, Haryana, India
| | - M. Kumar
- Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
| | - V. Singhal
- Vikram Hospital, Yamuna Nagar, Haryana, India
| | - A.M. Patel
- Yashdeep Hospital, Gandhinagar, Gujarat, India
| | - A. Khunt
- Sehat Hospital, Juhapura, Gujarat, India
| | - R. Shah
- Panth Children Hospital, Gujarat, India
| | - S. Wazeer
- Cloudnine Hospital, Gurugram, Haryana, India
| | - R. Rathod
- Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, India
| | - A. Mane
- Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, India
| | - S. Mehta
- Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, India
| | - K.C. Veligandla
- Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, India
- Corresponding author: K.C. Veligandla, Dr. Reddy's Laboratories Ltd., 7-1-27, Greenlands, Ameerpet, Hyderabad, 500016, India.
| |
Collapse
|
5
|
Apaolaza PS, Busch M, Asin-Prieto E, Peynshaert K, Rathod R, Remaut K, Dünker N, Göpferich A. Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution. Exp Eye Res 2020; 198:108151. [PMID: 32721426 DOI: 10.1016/j.exer.2020.108151] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 07/03/2020] [Accepted: 07/14/2020] [Indexed: 12/14/2022]
Abstract
Due to the unique anatomical structure of the eye, ocular drug delivery is a promising delivery route for the treatment of several ocular diseases, such as the ocular neovascularization that contributes to diabetic retinopathy. This disease is triggered by inflammation, retinal ischemia, and/or deposits of advanced-glycation end-products (AGEs), as well as increased levels of vascular endothelial growth factor (VEGF), interleukins, or reactive oxygen species (ROS). Gold has unique antioxidant and antiangiogenic properties and can inhibit angiogenic molecules. Furthermore, gold nanoparticles (GNPs) are not only biocompatible, they are easy to synthesize, they absorb and scatter visible light, and they can be made with precise control over size and shape. GNPs are an excellent candidate for ocular drug delivery because they can be conjugated to an extraordinarily diverse array of different biomolecules, and surface functionalization can improve the mobility of GNPs across the physiological barriers of the eye, such as the vitreous humour or the inner limiting membrane. For this purpose, we employed low molecular weight hyaluronan (HA) to increase the mobility of the nanoparticles as well as target them to HA receptors that are expressed in different cells of the eye. In this study, the combination of gold and HA enhanced the stability of the whole carrier and promoted their distribution across ocular tissues and barriers to reach the retina. Moreover, analysis in vitro, ex vivo, and in ovo revealed the protective and antiangiogenic effect of GNPs as inhibitors of AGEs-mediated- retinal pigment epithelial cell death and neovascularization. We demonstrated that conjugation with HA enhances GNP stability and distribution due to a specific CD44 receptor interaction. The capacity of HA-GNPs to distribute through the vitreous humour and their avidity for the deeper retinal layers ex vivo, suggest that HA-GNPs are a promising delivery system for the treatment of ocular neovascularization and related disorders.
Collapse
Affiliation(s)
- P S Apaolaza
- Department of Pharmaceutical Technology, University of Regensburg, Universitätsstraße 31, D, 93053, Regensburg, Germany
| | - M Busch
- Medical Faculty, Institute for Anatomy II, Department of Neuroanatomy, University of Duisburg-Essen, Hufelandstraße. 55, D-45122, Essen, Germany
| | - E Asin-Prieto
- Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, Irunlarrea s/n, 31008, Pamplona, Spain
| | - K Peynshaert
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium
| | - R Rathod
- Department of Pharmaceutical Technology, University of Regensburg, Universitätsstraße 31, D, 93053, Regensburg, Germany
| | - K Remaut
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium
| | - N Dünker
- Medical Faculty, Institute for Anatomy II, Department of Neuroanatomy, University of Duisburg-Essen, Hufelandstraße. 55, D-45122, Essen, Germany
| | - A Göpferich
- Department of Pharmaceutical Technology, University of Regensburg, Universitätsstraße 31, D, 93053, Regensburg, Germany.
| |
Collapse
|
6
|
Alizadeh M, Antoniou S, Fhadil S, Rathod R, Guttmann O, Knight C, Timmis A, Wragg A, Mathur A, Jones DA, Baumbach A, Weeraman D, Beirne A. P6426The use of direct oral anti-coagulations (DOACs) compared to vitamin k antagonist in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.1020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Aim
Current guidelines recommend the use of Vitamin K Antagonist (VKA) for up to 3–6 months for the treatment of LV thrombus post- acute myocardial infarction (AMI). However based on evidence supporting the non-inferiority and potential superiority of Direct Oral Anti-Coagulation's (DOAC) compared to VKA for other indications such as atrial fibrillation, DOACs are being increasingly used off licence for the treatment of left ventricular (LV) thrombus post AMI. In this study we investigated the effect of DOACs compared to VKA on LV thrombus resolution and their safety profile in patients presenting with AMI.
Methods and results
This was a prospective observational study of 2,328 consecutive patients undergoing Percutaneous Coronary Intervention (PCI) for AMI between 2015- 2018, at a UK cardiac centre. Patients' details were collected from the hospital electronic database. The primary end-point was the rate of resolution of LV thrombus with bleeding rates as a secondary outcome.
Left ventricular (LV) thrombus was diagnosed by echocardiography, or cardiac magnetic resonance imaging in 98 (5.1%) patients. Sixty patients (61.2%) were started on VKA and 38 patients (38.8%) on DOAC therapy (Rivaroxaban: 57.9%, Apixaban, 36.8% and Edoxaban: 5.3%). Both groups were well matched in terms of baseline characteristics including age, previous cardiac history (previous MI, PCI, CABG), and cardiovascular risk factors (Hypertension, Diabetes, Hypercholesterolaemia).
Over the follow up period (median 1.8 years), overall rates of LV thrombus resolution were 86%. There was greater and earlier LV thrombus resolution in the DOAC group compared to patients treated with warfarin (75% vs 53%, p=0.0018, at 1 year), which persisted after adjusting for baseline variables (OR 1.8 95% CI 1.2–2.9). Major bleeding such as intracranial bleed, major GI bleed and bleed requiring hospital admission were lower in DOAC group, compared with VKA group (0% vs 5%, p=0.030) with no difference in rates of systemic thromboembolism (p=0.388).
Conclusion
This data suggests improved thrombus resolution in post ACS LV thrombosis in patient treated with DOACs compared to vitamin K antagonists. This improvement in thrombus resolution was accompanied with a better safety profile for the DOAC patients' vs VKA treated patients. This supports the need for randomised controlled trials to confirm this observational data.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- M Alizadeh
- Barts Health NHS Trust, London, United Kingdom
| | - S Antoniou
- Barts Health NHS Trust, London, United Kingdom
| | - S Fhadil
- Barts Health NHS Trust, London, United Kingdom
| | - R Rathod
- Barts Health NHS Trust, London, United Kingdom
| | - O Guttmann
- Barts Health NHS Trust, London, United Kingdom
| | - C Knight
- Barts Health NHS Trust, London, United Kingdom
| | - A Timmis
- Barts Health NHS Trust, London, United Kingdom
| | - A Wragg
- Barts Health NHS Trust, London, United Kingdom
| | - A Mathur
- Barts Health NHS Trust, London, United Kingdom
| | - D A Jones
- Barts Health NHS Trust, London, United Kingdom
| | - A Baumbach
- Barts Health NHS Trust, London, United Kingdom
| | - D Weeraman
- Barts Health NHS Trust, London, United Kingdom
| | - A Beirne
- Barts Health NHS Trust, London, United Kingdom
| |
Collapse
|
7
|
Jain MR, Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, Ranvir R, Kadam S, Patel H, Swain P, Roy SS, Das N, Karmakar E, Wahli W, Patel PR. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int 2018; 38:1084-1094. [PMID: 29164820 PMCID: PMC6001453 DOI: 10.1111/liv.13634] [Citation(s) in RCA: 141] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 11/13/2017] [Indexed: 12/12/2022]
Abstract
BACKGROUND & AIMS Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common clinico-pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH. METHODS & RESULTS HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFα, IL1β and IL6). These effects were blocked by saroglitazar, pioglitazone and fenofibrate (all tested at 10μM concentration). Furthermore, these agents reversed PA-mediated changes in mitochondrial dysfunction, ATP production, NFkB phosphorylation and stellate cell activation in HepG2 and HepG2-LX2 Coculture studies. In mice with choline-deficient high-fat diet-induced NASH, saroglitazar reduced hepatic steatosis, inflammation, ballooning and prevented development of fibrosis. It also reduced serum alanine aminotransferase, aspartate aminotransferase and expression of inflammatory and fibrosis biomarkers. In this model, the reduction in the overall NAFLD activity score by saroglitazar (3 mg/kg) was significantly more prominent than pioglitazone (25 mg/kg) and fenofibrate (100 mg/kg). Pioglitazone and fenofibrate did not show any improvement in steatosis, but partially improved inflammation and liver function. Antifibrotic effect of saroglitazar (4 mg/kg) was also observed in carbon tetrachloride-induced fibrosis model. CONCLUSIONS Saroglitazar, a dual PPARα/γ agonist with predominant PPARα activity, shows an overall improvement in NASH. The effects of saroglitazar appear better than pure PPARα agonist, fenofibrate and PPARγ agonist pioglitazone.
Collapse
Affiliation(s)
- Mukul R. Jain
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | - Suresh R. Giri
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | - Bibhuti Bhoi
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | - Chitrang Trivedi
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | - Akshyaya Rath
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | - Rohan Rathod
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | | | - Shekhar Kadam
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | - Hiren Patel
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | - Prabodha Swain
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| | - Sib Sankar Roy
- Cell Biology and Physiology DivisionIndian Institute of Chemical BiologyKolkataIndia
| | - Nabanita Das
- Cell Biology and Physiology DivisionIndian Institute of Chemical BiologyKolkataIndia
| | - Eshani Karmakar
- Cell Biology and Physiology DivisionIndian Institute of Chemical BiologyKolkataIndia
| | - Walter Wahli
- Lee Kong Chian School of MedicineNanyang Technological UniversitySingaporeSingapore
| | - Pankaj R. Patel
- Zydus Research CentreCadila Healthcare LimitedAhmedabadGujaratIndia
| |
Collapse
|
8
|
Bhadke B, Rathod R, Deshmukh D, Luniya A. Study of various causes of defaulter among tuberculosis patients under revised national tuberculosis control programme: a prospective analysis of 5235 tuberculosis patients. ACTA ACUST UNITED AC 2016. [DOI: 10.18203/2320-6012.ijrms20161920] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
9
|
Kalra S, Sahay RK, Schnell O, Sheu W, Grzeszczak W, Watada H, Soegondo S, Yamamoto N, Weng J, Rathod R. Acarbose improves glycemic control and reduces body weight: Subanalysis data of South Asia region. Indian J Endocrinol Metab 2013; 17:S304-S306. [PMID: 24251195 PMCID: PMC3830341 DOI: 10.4103/2230-8210.119632] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Alpha-glucosidase inhibitors (AGIs) are widely used especially in Asian countries as a treatment option for type 2 diabetes patients with high postprandial glycaemia. However, data from South Asia region is very limited. In order to examine the effect of AGI in real-life setting, 10 PMS/NIS from all over the world from the launch of acarbose to date were pooled in one database and exploratory analysis was performed for glycemic parameters and weight. In total 62,905 patients were pooled from 21 countries and regions. Mean follow up (± SD) was 12.2 ± 4.8 weeks (range 0.1-108.9). From South Asia region (India and Pakistan), 8,738 Asian patients were enrolled. Mean PPG decreased from 240.0 and 261.1 mg/dl at baseline by 70.26 ± 65.10 and 82.96 ± 56.59 mg/dl at the last visit in total and South Asian populations, respectively (n = 53,883; n = 7,991, P < 0.0001 for both). Mean FPG decreased from 171.6 and 176.5 mg/dl at baseline by 38.48 ± 47.83 and 49.59 ± 41.41 mg/dl at the last visit in total and South Asian populations, respectively (n = 56,672; n = 7,837, P < 0.0001 for both). Mean HbA1c decreased from 8.4 and 8.4% at baseline by 1.11 ± 1.31% and 0.91 ± 0.93% at the last visit in total and South Asian populations, respectively (n = 38,843; n = 2,343, P < 0.0001 for both). Mean relative reduction of body weight (BW) was 1.40 ± 3.28% and 1.10 ± 3.39% at the last visit for mean baseline BW 73.6 and 74.2 kg in total and South Asian populations, respectively (n = 54,760; n = 7,718, P < 0.0001 for both). Consistent with RCT meta-analyses, post-hoc analysis of real-life data showed acarbose treatment improved glycaemic control and reduced the BW. Acarbose treatment in real life setting showed significant reductions in all glycemic parameters and BW in Asian patients from South Asia region.
Collapse
Affiliation(s)
- S Kalra
- Bharti Research Institute of Diabetes and Endocrinology Bharti Hospital, Department of Endocrinology, Karnal, India
| | - R. K. Sahay
- Department of Endocrinology, Osmania Medical College, Hyderabad, India
| | - O. Schnell
- Forschergruppe Diabetes e.V. at the Helmholtz Center Munich, Munich, Germany
| | - W.H.H. Sheu
- Taichung Veterans General Hospital, Department of Internal Medicine, Taichung, Taiwan
| | - W. Grzeszczak
- Medical University of Silesia, Department of Internal Medicine, Zabrze, Poland
| | - H. Watada
- Juntendo University Graduate School of Medicine, Department of Endocrinology and Metabolism, Tokyo, Japan
| | - S. Soegondo
- University of Indonesia, Department of Internal Medicine, Jakarta, Indonesia
| | - N. Yamamoto
- Bayer Healthcare, Global Medical Affairs, Beijing, China
| | - J. Weng
- The Third Affiliated Hospital of Sun Yat Sen University, Department of Endocrinology, Guangzhou, China
| | - R. Rathod
- Bayer Healthcare, Bayer Zydus Pharma Private Limited, Thane, India
| |
Collapse
|
10
|
Kalra S, Sahay RK, Schnell O, Sheu WHH, Grzeszczak W, Watada H, Soegondo S, Yamamoto N, Weng J, Rathod R. Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis. Indian J Endocrinol Metab 2013; 17:S307-S309. [PMID: 24251196 PMCID: PMC3830342 DOI: 10.4103/2230-8210.119634] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Alpha-glucosidase inhibitors are widely used especially in Asian countries as a treatment option for type 2 diabetes patients with high postprandial glycemia (PPG). The higher carbohydrate in the Indian diets lead to greater prandial glycemic excursion, increased glucosidase, and incretin activity in the gut and may need special therapeutic strategies to tackle these glucose peaks. This is the subgroup analysis of Indian subjects who participated in the GlucoVIP study that investigated the effectiveness and tolerability of acarbose as add-on or monotherapy in a range of patients with type 2 diabetes mellitus. A total of 1996 Indian patients were included in the effectiveness analysis. After 12.5 weeks (mean), the mean change in 2-hour PPG from baseline was -74.4 mg/dl, mean HbA1c decreased by -1.0%, and mean fasting blood glucose decreased by -37.9 mg/dl. The efficacy of acarbose was rated "very good" or "good" in 91.1% of patients, and tolerability as "very good" or "good" in 88.0% of patients. The results of this observational study suggest that acarbose was effective and well tolerated in the Indian patients with T2DM.
Collapse
Affiliation(s)
- Sanjay Kalra
- Department of Endocrinology, Bharti Research Institute of Diabetes and Endocrinology Bharti Hospital, Karnal, India
| | - R. K. Sahay
- Department of Endocrinology, Osmania Medical College, Hyderabad, India
| | - O. Schnell
- Forschergruppe Diabetes e.V. at the Helmholtz Center Munich, Munich, Germany
| | - W. H. H. Sheu
- Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
| | | | - H. Watada
- Endocrinology and Metabolism, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | | | - N. Yamamoto
- Bayer Healthcare, Global Medical Affairs, Beijing, China
| | - J. Weng
- The Third Affiliated Hospital of Sun Yat Sen University, Guangzhou, China
| | - R. Rathod
- Bayer Healthcare, Bayer Zydus Pharma Private Limited, Thane, India
| |
Collapse
|
11
|
Hanumanthayya K, Magavi S, Tophakhane R, Rathod R. Coexistence of disseminated superficial and giant porokeratosis of Mibelli with squamous cell carcinoma. Indian J Dermatol Venereol Leprol 2003; 69:296-7. [PMID: 17642918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Porokeratosis of Mibelli is a genetic disease transmitted as an autosomal dominant trait. The giant type of porokeratosis is a relatively rare entity and is associated with an increased risk of malignancy. The aim of this article is to present this rare case of giant porokeratosis associated with squamous cell carcinoma.
Collapse
Affiliation(s)
- K Hanumanthayya
- Department of Skin, STD and Leprosy, Karnataka Institute of Medical Sciences, Hubli
| | | | | | | |
Collapse
|
12
|
Rathod R, Pechstedt RD, Jackson DA, Webb DJ. Distributed temperature-change sensor based on Rayleigh backscattering in an optical fiber. Opt Lett 1994; 19:593-595. [PMID: 19844383 DOI: 10.1364/ol.19.000593] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A frequency-modulated continuous-wave technique is used to detect the presence of frequency shifts in the Rayleigh-backscattered light in a single-mode optical fiber as a result of a changing temperature. The system is able to detect a rate of temperature change of 0.014 K/s, when a 20-cm length of fiber is heated. The system is also able to demonstrate a spatial resolution of better than 15 cm.
Collapse
|
13
|
|
14
|
Abstract
A patient of faintly marfanoid habitus with left venticular failure, aortic regurgitation, and rate-related left bundle-branch block was found to have a midsystolic click and echocardiographic findings suggestive of mitral valve prolapse; however, the click did not move earlier in systole in response to head-up tilt or atrial pacing. Cardiac catheterization and angiocardiographic studies revealed severe left ventricular dysfunction out of proportion to the moderate amount of aortic regurgitation observed on aortographic study. Mitral valve prolapse was not confirmed by left ventriculographic study. Intracardiac phonocardiographic and catheter-tip manometric studies identified the click as being aortic in origin, ejection in timing, and midsystolic, rather than early systolic, because of delayed aortic valve opening related to left ventricular dysfunction and delay in conduction.
Collapse
|
15
|
|
16
|
Rathod R, Jacobs HK, Kramer NE, Rao LK, Salem MR, Towne WD. Echocardiographic assessment of ventricular performance following induction with two anesthetics. Anesthesiology 1978; 49:86-90. [PMID: 686431 DOI: 10.1097/00000542-197808000-00004] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Echocardiographic studies were made of 20 healthy patients scheduled for minor surgical procedures to determine whether this technique could be used routinely in the operating room and to evaluate the effects of halothane and enflurane on left ventricular performance. Thirteen minutes following induction of anesthesia with halothane in ten patients (mean end-tidal halothane concentration 0.93 per cent), mean arterial blood pressure, left ventricular (LV) diastolic dimension, LV fractional shortening, mean velocity of circumferential fiber shortening and systolic thickening of the posterior LV wall were significantly decreased. LV systolic dimension was increased significantly. These data indicate that halothane caused decreased contractility in the presence of a decreased afterload. Twelve minutes following induction of anesthesia with enflurane in ten patients (mean delivered enflurane concentration 2.4 per cent), mean arterial blood pressure and LV systolic and diastolic dimensions were decreased, while heart rate was increased significantly, indicating that enflurane caused vasodilatation and may have had some depressant effect on contractility. Echocardiography is a non-invasive, safe and relatively rapid method that can be used in the perioperative period to assess cardiac function and to evaluate the effects of pharmacologic agents on the heart.
Collapse
|